BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marelli S, Pace F. Rabeprazole for the treatment of acid-related disorders. Expert Rev Gastroenterol Hepatol. 2012;6:423-435. [PMID: 22928894 DOI: 10.1586/egh.12.18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Gesheff MG, Franzese CJ, Bliden KP, Contino CJ, Rafeedheen R, Tantry US, Gurbel PA. Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin. Expert Review of Clinical Pharmacology 2014;7:645-53. [DOI: 10.1586/17512433.2014.945428] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
2 Fang H, Jin L, Huang N, Wang J, Zou K, Luo Z. Synthesis, Structure and H + /K + -ATPase Inhibitory Activity of Novel Triazolyl Substituted Tetrahydrobenzofuran Derivatives via One-pot Three-component Click Reaction. Chin J Chem 2013;31:831-6. [DOI: 10.1002/cjoc.201300119] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Yoneda T, Hiasa M, Nagata Y, Okui T, White FA. Acidic microenvironment and bone pain in cancer-colonized bone. Bonekey Rep 2015;4:690. [PMID: 25987988 DOI: 10.1038/bonekey.2015.58] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
4 Shu X, Zhu Z, Fu Y, Zhang Z, Wang J, Li X, He S, Fan H, Liu S, Zhang G, Tang J, Huang C, Du Q, Wang X, Xu B, Du Y, Chen Q, Wang B, Chen Y, Duan X, Xie Y, Huo L, Hou X, Lu N. Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial. Front Med (Lausanne) 2021;8:690995. [PMID: 34336894 DOI: 10.3389/fmed.2021.690995] [Reference Citation Analysis]
5 Yoneda T, Hiasa M, Okui T, Hata K. Sensory nerves: A driver of the vicious cycle in bone metastasis? J Bone Oncol 2021;30:100387. [PMID: 34504741 DOI: 10.1016/j.jbo.2021.100387] [Reference Citation Analysis]
6 Li W, Zeng S, Yu LS, Zhou Q. Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag 2013;9:259-71. [PMID: 23745048 DOI: 10.2147/TCRM.S43151] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
7 Dugalic P, Djuranovic S, Pavlovic-Markovic A, Dugalic V, Tomasevic R, Gluvic Z, Obradovic M, Bajic V, Isenovic ER. Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus. Mini Rev Med Chem 2020;20:975-87. [PMID: 31644405 DOI: 10.2174/1389557519666191015203636] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Yoneda T, Hiasa M, Nagata Y, Okui T, White F. Contribution of acidic extracellular microenvironment of cancer-colonized bone to bone pain. Biochim Biophys Acta 2015;1848:2677-84. [PMID: 25687976 DOI: 10.1016/j.bbamem.2015.02.004] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
9 Gu M, Zhang Y, Zhou X, Ma H, Yao H, Ji F. Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines. Oncol Lett 2014;8:1739-44. [PMID: 25202402 DOI: 10.3892/ol.2014.2354] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
10 Li H, Shi FH, Liu F, Chen H, Wang YQ, Gong XJ, Wei JF. H+/K+-ATPase inhibitors and acid-related disorders. Shijie Huaren Xiaohua Zazhi 2014; 22(15): 2073-2080 [DOI: 10.11569/wcjd.v22.i15.2073] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Mousavi T, Nikfar S, Abdollahi M. The pharmacotherapeutic management of duodenal and gastric ulcers. Expert Opin Pharmacother 2021;:1-27. [PMID: 34435515 DOI: 10.1080/14656566.2021.1959914] [Reference Citation Analysis]